Medicare Negotiation And The Politics Of Drug Pricing
Medicare pricing decisions will become ‘highly politicized,’ Scott Gottlieb predicts. The former FDA commissioner and CMS official also believes the program should rely on outside health technology assessment groups, and he offers his opinions on how negotiation will (or won’t) change patent litigation.
You may also be interested in...
Biogen CEO Poses Million Dollar Question – Do We Need To Spend On Weight Loss Drugs?
As demand for Wegovy busts through capacity, Biogen’s Viehbacher asks if we need to spend on drugs for weight loss or other preventable diseases when the dollar could go towards non-preventable chronic diseases. Discussing investments at a recent conference, he was joined by Fidelity’s Rajiv Kaul who said the concept of therapeutic classes is outdated
Medicare Price Negotiation And A New Twist On Product Hopping
Tactic generally used to foil generic or biosimilar competition may find a new use in combination with such competition to avoid price negotiation, legal experts observe.
A Level Playing Field? Medicare Tries To Balance Transparency, Confidentiality With Drug Price Negotiations
Drug manufacturers may want more ability to communicate about their drug price negotiation experience with Medicare than CMS is proposing, but if that jeopardizes protections for proprietary information, it may not be worthwhile.